Medincell, AbbVie to Co-Develop Injectable Therapeutics
AbbVie Inc ABBV
News
-
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
AbbVie on Pace for Largest Percent Decrease Since October 2023 — Data Talk
AbbVie to Host First-Quarter 2024 Earnings Conference Call
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024